about
Definition of treatment goals for moderate to severe psoriasis: a European consensusApremilast in the therapy of moderate-to-severe chronic plaque psoriasisRelationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?Annular Lichenoid Dermatitis of Youth: Report of Six New Cases with Review of the LiteratureConsiderations for Systemic Treatment of Psoriasis in Obese Patients.Heat urticaria: a revision of published cases with an update on classification and management.Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapyTargeting tumor necrosis factor-alpha in the therapy of psoriasis.Folic acid in general medicine and dermatology.Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern.Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm.Concept of Remission in Chronic Plaque Psoriasis.Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis.Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey.Efficacy of a single educative intervention in patients with chronic plaque psoriasis.Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis.Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire.Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis.Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.Therapeutic insights from the British Association of Dermatologists Biologic Interventions Register.Management of patients with psoriasis treated with biological drugs needing a surgical treatment.Glomerular filtration rate in patients with psoriasis treated with etanerceptUsefulness of the framingham risk score in patients with chronic psoriasis.Comparison of patients' and providers' severity evaluation of oral mucosal conditions.Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.The diagnostic and therapeutic challenge of early psoriatic arthritis.The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development.An itchy vesiculobullous eruption in a patient with chronic lymphocytic leukaemia.Dermatoepidemiology; what's up people?Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.Hyperuricemia in patients with chronic plaque psoriasis.Incidence of respiratory and allergic symptoms in Italian and immigrant children.A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis.Chronic plaque psoriasis is associated with increased arterial stiffness.Combination of efalizumab and acitretin in chronic plaque psoriasis.
P50
Q24604445-B7F67417-0AF3-4808-892D-3173EA87D386Q26745789-78494650-268D-4AD9-A9FE-C1D04480C3FCQ26767276-D88C9FA7-D2D5-4AB4-9EC7-8251472D99F9Q28082881-06302BC9-6731-4817-94E8-02B9908BA135Q30249013-40050DC4-F643-4820-B0ED-36B41FA3DE67Q33166940-913731ED-585B-4D01-ABE3-CA75482A74FDQ33785074-97B6D9BB-B845-47A8-ACAA-22B9BBDC2C88Q35793837-B6C636E2-4CE0-4430-9069-BF2AD156CEC2Q36835583-EE5AD90F-A17E-49FE-8159-C4193DB455E6Q37953452-E1CAF70D-9F8D-4B7A-85A2-54A8F18FF4EAQ37972320-DA7A933F-E191-45DE-BF7A-F5F65EA0F38EQ38150903-D9B068AE-1AA1-4474-9E12-576C65058CC0Q38265056-0684FDB1-9F90-4C82-AF64-DD21DCAB6FF6Q38622069-5D565542-B29F-4B35-8221-6146F6BEDF29Q38694987-FC612445-8C1A-4E2B-8D1E-0A6A0D89A797Q38838470-2DF63A34-4B1E-4EDA-9652-98A4436902C9Q38986603-9AC1E6E3-21FF-46FD-ADC3-146D4E1B7655Q39165009-B8BED2BD-D973-439F-B8E6-BD6939C1DFA7Q39296901-91CFC5B8-9F38-427E-97F4-74CAEDEBD598Q39574808-B7E0EB69-10F8-4944-BBFE-A6355D1AF396Q39694915-4CA58391-168D-4B28-A943-DD5BD04229DAQ40197638-7EFF0602-402E-4B26-9289-A9AC223B7D33Q40319405-7816AF36-4AF1-4A48-BBEC-3A6DDD3BD9FEQ41150051-9262A0CB-DD9D-4030-BFBA-FD799E83EDCCQ41395652-9E511B16-F445-42A6-8518-D1CEAC0E824BQ41670448-CEFBD6C6-64BE-46B4-B9EB-7D014B587F50Q41789060-6151672A-61DA-4D1B-AC14-67742B36A5B8Q42833927-2BB071BC-3017-49B6-8BE7-0B503D552E54Q43666207-C834DAF3-61BF-41B1-86E7-427B1C9158CFQ44104600-4B1FAA84-96FC-485C-A4BC-DCECA7A19BB0Q44305067-84201F4E-8EDF-477D-9D32-D53CFF4C55B8Q44515219-2EB1897E-79C7-4301-BFE7-1156C7EBB9E4Q45221272-9C469634-ED79-4927-AB42-CC71A2688449Q45358210-766AB3B5-7E81-47DC-A484-C80E35D9FAB3Q45761302-D96A4A85-D8FA-4CA6-87D6-DC7F4F4289E8Q45777355-7B72B01B-0F95-4B22-9B96-45C99A26902CQ46094572-9B18E96D-F2B8-4BB5-ACAF-82CBABB326D1Q46142814-22491A91-E893-4A65-80A1-AB9D76278CBAQ46211645-FE50D0F1-0DCD-41B6-9DCC-4C74EE55A483Q46797196-65BC1F13-9727-4E21-B8A4-57400A7FD554
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Gisondi
@ast
Paolo Gisondi
@en
Paolo Gisondi
@es
Paolo Gisondi
@nl
type
label
Paolo Gisondi
@ast
Paolo Gisondi
@en
Paolo Gisondi
@es
Paolo Gisondi
@nl
prefLabel
Paolo Gisondi
@ast
Paolo Gisondi
@en
Paolo Gisondi
@es
Paolo Gisondi
@nl
P106
P1153
8515785100
P31
P496
0000-0002-1777-9001